Amphiregulin: a new growth factor in hepatocarcinogenesis.

Abstract

Amphiregulin (AR) is a member of the epidermal growth factor family and a ligand of the epidermal growth factor receptor (EGFR). As other ligands of the EGFR, AR is synthesized as a precursor that is shed from the plasma membrane by metalloproteases. Hyperactive autocrine loops involving AR production have been described in a variety of tumors, and this growth factor is thought to play a non-redundant role in cancer development. AR expression is not detected in the normal liver, however it is readily induced during acute liver injury and behaves as a potent pro-regenerative and survival factor. Increased AR expression is also detected in human chronic liver injury (liver cirrhosis), which is considered a pre-neoplastic condition. Recent evidences suggest that AR can play a unique role in liver tumorigenesis and in the maintenance of the neoplastic phenotype of hepatocarcinoma cells. In this review, we summarize some aspects of AR patho-biology and the rationale behind its definition as a novel target in hepatocarcinoma therapy.

01002003002008200920102011201220132014201520162017
Citations per Year

703 Citations

Semantic Scholar estimates that this publication has 703 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Berasain2007AmphiregulinAN, title={Amphiregulin: a new growth factor in hepatocarcinogenesis.}, author={Carmen Berasain and Jorge Castillo and Maria J Perugorria and Jos{\'e} Pedro Prieto and Mat{\'i}as A. Avila}, journal={Cancer letters}, year={2007}, volume={254 1}, pages={30-41} }